[go: up one dir, main page]

MA46780A - Esters à dchbs actif de composés peg et leur utilisation - Google Patents

Esters à dchbs actif de composés peg et leur utilisation

Info

Publication number
MA46780A
MA46780A MA046780A MA46780A MA46780A MA 46780 A MA46780 A MA 46780A MA 046780 A MA046780 A MA 046780A MA 46780 A MA46780 A MA 46780A MA 46780 A MA46780 A MA 46780A
Authority
MA
Morocco
Prior art keywords
dchbs
esters
active
peg compounds
peg
Prior art date
Application number
MA046780A
Other languages
English (en)
Inventor
Fredrik Gustafsson Magnus Bernt
Jensen Kim Birkebaek
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA46780A publication Critical patent/MA46780A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/41Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
    • C07C309/42Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/16Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/023General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02Polyalkylene oxides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00Applications
    • C08L2203/02Applications for biomedical use

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA046780A 2016-11-07 2017-11-07 Esters à dchbs actif de composés peg et leur utilisation MA46780A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16197464 2016-11-07
EP17181621 2017-07-17

Publications (1)

Publication Number Publication Date
MA46780A true MA46780A (fr) 2019-09-11

Family

ID=60388017

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046780A MA46780A (fr) 2016-11-07 2017-11-07 Esters à dchbs actif de composés peg et leur utilisation

Country Status (7)

Country Link
US (1) US11787837B2 (fr)
EP (1) EP3534962B1 (fr)
JP (1) JP7076442B2 (fr)
CN (1) CN109922835B (fr)
ES (1) ES2828526T3 (fr)
MA (1) MA46780A (fr)
WO (1) WO2018083335A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR200400225Y1 (ko) * 2005-08-02 2005-11-03 김기룡 자동복귀 기능을 가지는 도로교통표지판 어셈브리
WO2016097108A1 (fr) * 2014-12-17 2016-06-23 Novo Nordisk A/S Dérivés de glp-1 et utilisations associées
KR20250065720A (ko) 2018-04-05 2025-05-13 썬 파마슈티칼 인더스트리스 리미티드 신규한 glp-1 유사체
WO2022090448A1 (fr) 2020-10-30 2022-05-05 Novo Nordisk A/S Nouveaux réactifs d'acylation
KR20230104118A (ko) * 2020-11-06 2023-07-07 노보 노르디스크 에이/에스 Glp-1 전구약물 및 이의 용도
TW202440619A (zh) 2020-12-18 2024-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
WO2023134712A1 (fr) * 2022-01-14 2023-07-20 Rezubio Pharmaceuticals Co., Ltd Composes antidiabétiques et compositions

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
PL351326A1 (en) 1999-03-17 2003-04-07 Novo Nordisk As Method for acylating peptides and novel acylating agents
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2007079755A1 (fr) * 2006-01-12 2007-07-19 Janus Beierholm Holding Aps Ré-immunisation et conception d'anticorps
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
EP2178910B1 (fr) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulines avec une fraction acyle comprenant des unités répétitives d'alkylène glycol contenant des acides aminés
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
US7670177B2 (en) 2008-06-17 2010-03-02 Tyco Electronics Corporation Electrical connector having floating alignment member
CN106317164A (zh) 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
WO2011080103A1 (fr) 2009-12-16 2011-07-07 Novo Nordisk A/S Dérivés à double acylation de glp-1
DK2696687T3 (en) * 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
CN103596973A (zh) 2011-06-10 2014-02-19 诺沃—诺迪斯克有限公司 多肽
MX354156B (es) 2011-12-29 2018-02-15 Novo Nordisk As Dipeptido que comprende un aminoacido no proteogenico.
ES2629735T3 (es) * 2012-05-08 2017-08-14 Novo Nordisk A/S Derivados de GLP-1 doblemente acilados
AU2014286234A1 (en) 2013-07-04 2015-12-17 Novo Nordisk A/S Derivatives of GLP-1 like peptides, and uses thereof
EP3033112B1 (fr) 2013-08-15 2020-10-07 Novo Nordisk A/S Dérivés glp-1 et leurs utilisations
KR20160065126A (ko) 2013-10-07 2016-06-08 노보 노르디스크 에이/에스 인슐린 유사체의 신규한 유도체
WO2015071356A1 (fr) 2013-11-15 2015-05-21 Novo Nordisk A/S Hpyy(1-36) présentant une subsitution bêta-homoarginine en position 35
SI3068421T1 (sl) 2013-11-15 2019-08-30 Novo Nordisk A/S Selektivne spojine PYY in njihova uporaba
CN105829350B (zh) * 2013-12-17 2021-01-08 诺和诺德股份有限公司 肠激酶可切割的多肽
TW201625671A (zh) 2014-09-04 2016-07-16 諾佛 儂迪克股份有限公司 新穎澱粉素及降鈣素受體促效劑
CN106999602B (zh) 2014-11-27 2022-02-01 诺和诺德股份有限公司 Glp-1衍生物及其用途
WO2016097108A1 (fr) 2014-12-17 2016-06-23 Novo Nordisk A/S Dérivés de glp-1 et utilisations associées

Also Published As

Publication number Publication date
EP3534962B1 (fr) 2020-08-19
JP7076442B2 (ja) 2022-05-27
CN109922835B (zh) 2023-08-04
JP2019535690A (ja) 2019-12-12
EP3534962A1 (fr) 2019-09-11
WO2018083335A1 (fr) 2018-05-11
US11787837B2 (en) 2023-10-17
ES2828526T3 (es) 2021-05-26
US20190263854A1 (en) 2019-08-29
CN109922835A (zh) 2019-06-21

Similar Documents

Publication Publication Date Title
MA46780A (fr) Esters à dchbs actif de composés peg et leur utilisation
MA44225A (fr) Sulfonylurées et composés apparentés et leur utilisation
MA45613A (fr) Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique
EP3302442A4 (fr) Formes galéniques et leur utilisation
MA47440A (fr) Sulfonylurées, composés apparentés, et leur utilisation
EP3610035A4 (fr) Compositions et méthodes de thérapie génique transitoire à stabilité améliorée
MA45709A (fr) Composés diazahétérobicycliques substitués et leur utilisation
EP3340916A4 (fr) Cathéter de cartographie à électrodes de haute densité
EP3411035A4 (fr) Composés aminothiazole et leur utilisation
MA43364A (fr) Composés d'alcènes tétrasubstitués et leur utilisation
CL2016002300A1 (es) Combinaciones de principios activos insecticidas y nematocidas
MA43284A (fr) Composés et leurs méthodes d'utilisation
EP3024824A4 (fr) Composés thérapeutiquement actifs et utilisation de ceux-ci
MA51224A (fr) Composés de sulfonamide et leur utilisation
MA45113A (fr) Composés mic-1 et leur utilisation
EP3420897A4 (fr) Cathéter à électrodes
EP3724206A4 (fr) Composés antisens conjugués et leur utilisation
EP3294395C0 (fr) Ensembles cathéters urinaires télescopiques
MA50440A (fr) Imidazopyridinamides substituées et leur utilisation
EP3152190C0 (fr) Composés bi-polycycliques de 18 à 20 éléments
EP3335233A4 (fr) Dessus de touche à éléments actifs
EP3344613A4 (fr) Composés hétéroaryle et leur utilisation comme médicaments thérapeutiques
MA44056A (fr) Anticorps anti-rispéridone et leur utilisation
EP3373907A4 (fr) Compositions pharmaceutiques à libération prolongée et méthodes d'utilisation
MA46896A (fr) Composés d'alcène tétrasubstitués et leur utilisation